의료 영상 시장 : 모달리티별, 구성 요소별, 용도별, 최종 사용자별, 해부 부위별, 도입 형태별 - 세계 시장 예측(2026-2032년)

The Medical Imaging Market is projected to grow by USD 57.56 billion at a CAGR of 5.44% by 2032.

Medical Imaging Executive Summary

Medical imaging is a clinical and operational cornerstone for early diagnosis, treatment planning, image-guided intervention, disease surveillance, and longitudinal care management. Demand is supported by well-established healthcare trends, including population aging, higher incidence of cancer and cardiovascular disease, expanded screening programs, trauma care requirements, and the rising burden of chronic conditions documented by global public health agencies.

The medical imaging landscape spans X-ray, computed tomography, magnetic resonance imaging, ultrasound, mammography, nuclear imaging, fluoroscopy, interventional imaging, picture archiving and communication systems, vendor-neutral archives, and advanced visualization platforms. Purchasing decisions are increasingly shaped by diagnostic accuracy, workflow productivity, radiation dose optimization, interoperability, cybersecurity, lifecycle cost, regulatory compliance, and measurable clinical outcomes.

Transformative Shifts Reshaping Medical Imaging

Medical imaging is shifting from standalone equipment procurement to connected, data-driven imaging ecosystems. Hospitals, diagnostic networks, and outpatient centers are prioritizing cloud-enabled image management, enterprise imaging, teleradiology, mobile and point-of-care systems, and standardized data exchange through DICOM, HL7, and FHIR-aligned workflows.

Technology cycles are also accelerating. Photon-counting CT, low-field and portable MRI, handheld ultrasound, digital pathology integration, theranostics, hybrid imaging, and advanced nuclear imaging are expanding clinical use cases. At the same time, healthcare providers are responding to radiologist shortages, cost pressures, sustainability targets, cybersecurity risk, and stricter regulatory expectations, making service models, uptime guarantees, and evidence-backed performance increasingly important differentiators.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative impact across the medical imaging value chain. Public regulatory databases, including the U.S. FDA list of AI/ML-enabled medical devices, consistently show radiology as one of the largest categories for cleared AI applications. Current use cases include image triage, detection support, organ segmentation, reconstruction, dose optimization, reporting assistance, scheduling, and quality assurance.

The strongest commercial opportunities are emerging where AI improves throughput, reduces repeat scans, supports earlier detection, and helps radiology teams manage growing exam volumes. However, adoption depends on clinical validation, bias testing, workflow integration, post-market monitoring, cybersecurity controls, physician oversight, and reimbursement clarity. Vendors and providers that pair algorithms with enterprise-grade deployment, auditability, and measurable outcomes are best positioned for durable adoption.

Key Regional Insights

Asia-Pacific is expanding through hospital infrastructure investment, rising health insurance coverage, domestic manufacturing, and large patient populations in China and India, while Japan, South Korea, and Australia remain important adopters of advanced MRI, CT, ultrasound, nuclear imaging, and AI-enabled workflow tools. North America continues to lead in premium imaging adoption, FDA-cleared AI deployment, outpatient imaging networks, enterprise imaging modernization, and integrated radiology workflows, supported by high healthcare spending, established reimbursement pathways, and strong clinical research activity.

Latin America shows uneven but resilient demand, with Brazil and Mexico driving private-sector imaging investments, oncology diagnostics, cardiology imaging, and teleradiology adoption to address specialist concentration in major cities. Europe is shaped by replacement demand, EU Medical Device Regulation compliance, data privacy requirements, sustainability goals, structured screening programs, and strong public health systems. The Middle East, particularly GCC countries, is investing in tertiary hospitals, oncology centers, trauma care, and digital health infrastructure. Africa remains constrained by access gaps, equipment maintenance challenges, power reliability, and workforce shortages, but demand is rising for portable ultrasound, digital X-ray, tele-imaging, and public-private diagnostic capacity.

Key Group Insights

ASEAN demand is supported by healthcare infrastructure expansion, medical tourism, universal health coverage initiatives, and growing private hospital networks in Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. The GCC is accelerating adoption of advanced radiology, oncology imaging, hybrid imaging, and enterprise imaging as national health strategies prioritize specialized care, local capacity, digital transformation, and reduced reliance on outbound medical travel.

The European Union is a major regulatory and innovation bloc, with procurement influenced by MDR compliance, GDPR, health technology assessment, cybersecurity, interoperability, and energy efficiency. BRICS countries offer scale-driven opportunity through large patient populations, public hospital investments, domestic manufacturing policies, and expanding chronic disease diagnostics, although access and reimbursement vary widely. G7 markets remain central for premium systems, clinical research, AI validation, and advanced care pathways. NATO members add demand linked to military medical readiness, interoperable field imaging, trauma care, emergency response, and secure cross-border medical data exchange.

Key Country Insights

The United States is the largest high-value imaging market, driven by advanced hospital systems, outpatient imaging chains, AI clearance pathways, value-based care pressures, and strong replacement cycles. Canada emphasizes public system capacity, wait-time reduction, cancer and cardiovascular diagnostics, and imaging network modernization, while Mexico benefits from private hospital growth, diagnostic chain expansion, and cross-border healthcare demand. Brazil leads Latin American adoption, supported by large urban hospital networks and expanding oncology, cardiology, and maternal health imaging needs.

In Europe, the United Kingdom is focused on diagnostic capacity, community diagnostic centers, and National Health Service modernization; Germany remains a high-technology market with strong hospital infrastructure and advanced radiology adoption; France prioritizes public access and modernization; Italy and Spain balance replacement demand with regional procurement and public funding cycles; and Russia maintains demand for domestic capacity, large-scale diagnostic coverage, and import substitution efforts. China is scaling domestic innovation, hospital investment, and imaging access across tiered healthcare systems, India is expanding access through private chains, public programs, and tele-radiology, Japan prioritizes advanced modalities for an aging population, Australia invests in distributed care and teleradiology, and South Korea combines digital health strength, screening programs, and advanced imaging adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize interoperable platforms that connect modalities, PACS, VNA, reporting, AI orchestration, cybersecurity systems, and electronic health records. Product strategies should emphasize measurable improvements in diagnostic confidence, scan speed, dose reduction, uptime, energy efficiency, patient comfort, and total cost of ownership rather than hardware specifications alone.

Vendors and providers should build evidence-generation programs using multicenter validation, real-world performance monitoring, and health economic analysis. AI deployment requires governance for data quality, bias management, cybersecurity, model drift, regulatory documentation, and physician accountability. Growth strategies should also include regional partnerships, flexible financing, managed equipment services, workforce training, remote support, and localized service networks to improve adoption in both mature and emerging healthcare markets.

Research Methodology

The research methodology applies triangulated analysis combining primary interviews, secondary research, and analytical validation. Inputs include manufacturer disclosures, regulatory databases, hospital procurement signals, reimbursement updates, clinical guidelines, public health statistics, peer-reviewed literature, patent activity, import-export patterns, and technology adoption indicators.

Findings are validated through demand-side assessment, pricing analysis, technology benchmarking, regulatory review, procurement pattern analysis, and scenario review. Segmentation is evaluated across modality, application, end user, deployment model, geography, and technology maturity. Quality checks are performed to align interpretation with verified sources, regulatory realities, clinical evidence, and observable purchasing behavior across healthcare systems.

Conclusion

Medical imaging is entering a connected, intelligent, and outcomes-driven phase. Growth is no longer defined only by installed base expansion; it is increasingly determined by how effectively imaging assets improve care pathways, reduce diagnostic delays, support specialists, and integrate with digital health infrastructure.

Organizations that combine modality excellence with AI governance, enterprise interoperability, resilient service models, clinical evidence, cybersecurity readiness, and regional adaptation will be best positioned. As health systems confront rising exam volumes, workforce constraints, and cost pressures, medical imaging will remain essential to precision diagnosis, treatment planning, and efficient healthcare delivery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Medical Imaging Market, by Modality

• 7.1. Computed Tomography
  • 7.1.1. Cone Beam CT
  • 7.1.2. PET-CT
  • 7.1.3. Spectral CT
• 7.2. Magnetic Resonance Imaging
• 7.3. Nuclear Imaging
  • 7.3.1. Positron Emission Tomography
  • 7.3.2. Single Photon Emission Computed Tomography
• 7.4. Optical Imaging
• 7.5. Ultrasound
• 7.6. X Ray

8. Medical Imaging Market, by Component

• 8.1. Hardware
• 8.2. Services
  • 8.2.1. Installation & Integration
  • 8.2.2. Maintenance & Support
  • 8.2.3. Training & Education
• 8.3. Software

9. Medical Imaging Market, by Application

• 9.1. Cardiology
• 9.2. Gastroenterology
• 9.3. Neurology
• 9.4. Obstetrics & Gynecology
• 9.5. Oncology
• 9.6. Orthopedics
• 9.7. Urology

10. Medical Imaging Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Clinics
• 10.3. Diagnostic Imaging Centers
• 10.4. Hospitals

11. Medical Imaging Market, by Anatomy

• 11.1. Abdominal
• 11.2. Brain
• 11.3. Breast
• 11.4. Cardiovascular
• 11.5. Musculoskeletal
• 11.6. Pediatrics
• 11.7. Spine

12. Medical Imaging Market, by Deployment Mode

• 12.1. Cloud
• 12.2. On Premise

13. Medical Imaging Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Medical Imaging Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Medical Imaging Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Agfa-Gevaert Group
• 17.2. Analogic Corporation
• 17.3. Bracco Imaging S.p.A.
• 17.4. Bruker Corporation
• 17.5. Canon Medical Systems Corporation
• 17.6. Carestream Health, Inc.
• 17.7. Carl Zeiss Meditec AG
• 17.8. Esaote S.p.A.
• 17.9. Fujifilm Holdings Corporation
• 17.10. GE HealthCare Technologies Inc.
• 17.11. Hologic, Inc.
• 17.12. Konica Minolta, Inc.
• 17.13. Koninklijke Philips N.V.
• 17.14. Mindray Medical International Limited
• 17.15. MinFound Medical Systems
• 17.16. Neusoft Medical Systems
• 17.17. Olympus Corporation
• 17.18. Planmeca Oy
• 17.19. RadNet, Inc.
• 17.20. RapidAI by iSchemaView, Inc.
• 17.21. Samsung Medison Co., Ltd.
• 17.22. Sectra AB
• 17.23. Shimadzu Corporation
• 17.24. Siemens Healthineers AG
• 17.25. Skanray Technologies
• 17.26. United Imaging Healthcare
• 17.27. Varex Imaging Corporation
• 17.28. Ziehm Imaging